{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:16:56Z","timestamp":1790140616667,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Unitaid"},{"name":"National Science Foundation","award":["1722665"],"award-info":[{"award-number":["1722665"]}]},{"name":"National Science Foundation","award":["1722665"],"award-info":[{"award-number":["1722665"]}]},{"name":"National Science Foundation","award":["1722665"],"award-info":[{"award-number":["1722665"]}]},{"name":"National Science Foundation","award":["1722665"],"award-info":[{"award-number":["1722665"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The cost of testing can be a substantial contributor to hepatitis C virus (HCV) elimination program costs in many low- and middle-income countries such as Georgia, resulting in the need for innovative and cost-effective strategies for testing. Our objective was to investigate the most cost-effective testing pathways for scaling-up HCV testing in Georgia. We developed a Markov-based model with a lifetime horizon that simulates the natural history of HCV, and the cost of detection and treatment of HCV. We then created an interactive online tool that uses results from the Markov-based model to evaluate the cost-effectiveness of different HCV testing pathways. We compared the current standard-of-care (SoC) testing pathway and four innovative testing pathways for Georgia. The SoC testing was cost-saving compared to no testing, but all four new HCV testing pathways further increased QALYs and decreased costs. The pathway with the highest patient follow-up, due to on-site testing, resulted in the highest discounted QALYs (124 QALY more than the SoC) and lowest costs ($127,052 less than the SoC) per 10,000 persons screened. The current testing algorithm in Georgia can be replaced with a new pathway that is more effective while being cost-saving.<\/jats:p>","DOI":"10.1038\/s41598-021-00362-y","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T11:04:13Z","timestamp":1635764653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator"],"prefix":"10.1038","volume":"11","author":[{"given":"Madeline","family":"Adee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueran","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiyang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiannan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonjelle","family":"Shilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagpreet","family":"Chhatwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"362_CR1","unstructured":"World Health Organization. Global Hepatitis Report (2017)."},{"issue":"9","key":"362_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia, O. et al. Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review. Ann. Intern. Med. 166(9), 637\u2013648 (2017).","journal-title":"Ann. Intern. Med."},{"key":"362_CR3","unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030 (2016)."},{"issue":"3","key":"362_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2017","unstructured":"Blach, S. et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol. Hepatol. 2(3), 161\u2013176 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"362_CR5","doi-asserted-by":"publisher","first-page":"e193613","DOI":"10.1001\/jamanetworkopen.2019.3613","volume":"2","author":"J Chhatwal","year":"2019","unstructured":"Chhatwal, J. et al. Assessment of the feasibility and cost of hepatitis C elimination in Pakistan. JAMA Netw. Open 2(5), e193613 (2019).","journal-title":"JAMA Netw. Open"},{"key":"362_CR6","volume-title":"Polaris Observatory-Global Prevalence of Hepatitis C. Hepatology","year":"2016","unstructured":"Blach, S. et al. et al. (eds) Polaris Observatory-Global Prevalence of Hepatitis C. Hepatology (Wiley, 2016)."},{"issue":"3","key":"362_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12889-019-6784-3","volume":"19","author":"LM Hagan","year":"2019","unstructured":"Hagan, L. M. et al. Hepatitis C prevalence and risk factors in Georgia, 2015: Setting a baseline for elimination. BMC Public Health 19(3), 480 (2019).","journal-title":"BMC Public Health"},{"issue":"41","key":"362_CR8","first-page":"1132","volume":"65","author":"L Gvinjilia","year":"2016","unstructured":"Gvinjilia, L. et al. National progress toward hepatitis C elimination\u2014Georgia, 2015\u20132016. MMWR 65(41), 1132\u20131135 (2016).","journal-title":"MMWR"},{"key":"362_CR9","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1016\/S2214-109X(19)30483-8","volume":"8","author":"JG Walker","year":"2019","unstructured":"Walker, J. G. et al. Interim effect evaluation of the hepatitis C elimination programme in Georgia: A modelling study. Lancet Glob. Health. 8, e244\u2013e253 (2019).","journal-title":"Lancet Glob. Health."},{"issue":"2","key":"362_CR10","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/S2214-109X(19)30537-6","volume":"8","author":"Y Hutin","year":"2020","unstructured":"Hutin, Y., Luhmann, N. & Easterbrook, P. Evaluating the impact of Georgia\u2019s hepatitis C elimination plan: Lessons learned for the global initiative. Lancet Glob. Health. 8(2), e163\u2013e164 (2020).","journal-title":"Lancet Glob. Health."},{"issue":"6","key":"362_CR11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","volume":"16","author":"J Chhatwal","year":"2013","unstructured":"Chhatwal, J. et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 Infection in the United States. Value Health 16(6), 973\u2013986 (2013).","journal-title":"Value Health"},{"issue":"6","key":"362_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/M14-1336","volume":"162","author":"J Chhatwal","year":"2015","unstructured":"Chhatwal, J., Kanwal, F., Roberts, M. S. & Dunn, M. A. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann. Intern. Med. 162(6), 397\u2013406 (2015).","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"362_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S2468-1253(18)30281-4","volume":"3","author":"J Chhatwal","year":"2018","unstructured":"Chhatwal, J. et al. Hep C calculator: An online tool for cost-effectiveness analysis of DAAs. Lancet Gastroenterol. Hepatol. 3(12), 819 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"362_CR14","unstructured":"World Health Organization\u2014Viral Hepatitis Strategic Information and Modelling Reference Group. Meeting report | 14\u201316 June 2016 | WHO headquarters, Geneva, Switzerland (2016)."},{"key":"362_CR15","unstructured":"The World Factbook. Country comparisons\u2014median age. https:\/\/www.cia.gov\/the-world-factbook\/field\/median-age\/country-comparison2021."},{"key":"362_CR16","first-page":"71","volume":"165","author":"L Sharvadze","year":"2008","unstructured":"Sharvadze, L., Nelson, K. E., Imnadze, P., Karchava, M. & Tsertsvadze, T. Prevalence of HCV and genotypes distribution in general population of Georgia. Georgian Med. News. 165, 71\u201377 (2008).","journal-title":"Georgian Med. News."},{"key":"362_CR17","unstructured":"U.S. National Library of Medicine: ClinicalTrials.gov. Evaluation of HCV viremia testing approaches among PWID in Georgia (HEAD-Start): NCT03594838 (2020)."},{"issue":"20","key":"362_CR18","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal, N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370(20), 1889\u20131898 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"362_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson, D. R. et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61(4), 1127\u20131135 (2015).","journal-title":"Hepatology"},{"issue":"9","key":"362_CR20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1473-3099(15)00157-7","volume":"15","author":"A Kohli","year":"2015","unstructured":"Kohli, A. et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: A proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect. Dis. 15(9), 1049\u20131054 (2015).","journal-title":"Lancet Infect. Dis."},{"issue":"5","key":"362_CR21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","volume":"52","author":"AC Cardoso","year":"2010","unstructured":"Cardoso, A. C. et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J. Hepatol. 52(5), 652\u2013657 (2010).","journal-title":"J. Hepatol."},{"issue":"2","key":"362_CR22","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"H Thein","year":"2008","unstructured":"Thein, H., Yi, Q., Dore, G. & Krahn, M. Estimation of stage specific fibrosis progression rates in chronic hepatitis C virus infection: A meta analysis and meta regression. Hepatology 48(2), 418\u2013431 (2008).","journal-title":"Hepatology"},{"issue":"2","key":"362_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich, G. et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 112(2), 463\u2013472 (1997).","journal-title":"Gastroenterology"},{"issue":"5","key":"362_CR24","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jhep.2004.01.005","volume":"40","author":"R Planas","year":"2004","unstructured":"Planas, R. et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J. Hepatol. 40(5), 823\u2013830 (2004).","journal-title":"J. Hepatol."},{"issue":"4p2","key":"362_CR25","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1600-6143.2010.03021.x","volume":"10","author":"R Wolfe","year":"2010","unstructured":"Wolfe, R., Roys, E. & Merion, R. Trends in organ donation and transplantation in the United States, 1999\u20132008. Am. J. Transplant. 10(4p2), 961\u201372 (2010).","journal-title":"Am. J. Transplant."},{"issue":"3","key":"362_CR26","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","volume":"98","author":"CAKY Chong","year":"2003","unstructured":"Chong, C. A. K. Y. et al. Health-state utilities and quality of life in hepatitis C patients. Am. J. Gastroenterol. 98(3), 630\u2013638 (2003).","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"362_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989X06290497","volume":"26","author":"J Hanmer","year":"2006","unstructured":"Hanmer, J., Lawrence, W. F., Anderson, J. P., Kaplan, R. M. & Fryback, D. G. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med. Decis. Mak. 26(4), 391\u2013400 (2006).","journal-title":"Med. Decis. Mak."},{"issue":"3","key":"362_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/gut.52.3.425","volume":"52","author":"U Siebert","year":"2003","unstructured":"Siebert, U. et al. Cost effectiveness of peginterferon-2b plus ribavirin versus interferon-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52(3), 425 (2003).","journal-title":"Gut"},{"key":"362_CR29","unstructured":"Feasibility, acceptability, effectiveness and cost-analysis of models of HCV viremia testing for confirmation and cure among people who inject drugs (PWID): the HEAD-start trial in Georgia. Identifier: NCT03594838. Retrieved from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03594838 (2019)."},{"key":"362_CR30","unstructured":"Reuters. Gilead uses Georgia as free-drug test bed for hepatitis C elimination. 2015. Available from: https:\/\/www.reuters.com\/article\/us-health-hepatitis-gilead-georgia\/gilead-uses-georgia-as-free-drug-testbed-for-hepatitis-c-elimination-idUSKBN0ND1XU20150422 (last accessed 31 January 2020) (2015)."},{"issue":"13","key":"362_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11130","volume":"11","author":"J Wilson","year":"2007","unstructured":"Wilson, J. et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol. Assess. 11(13), 1\u2013202 (2007).","journal-title":"Health Technol. Assess."},{"issue":"1","key":"362_CR32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1186\/s12879-017-2773-2","volume":"17","author":"W Tang","year":"2017","unstructured":"Tang, W. et al. Diagnostic accuracy of tests to detect hepatitis C antibody: A meta-analysis and review of the literature. BMC Infect. Dis. 17(1), 695 (2017).","journal-title":"BMC Infect. Dis."},{"issue":"5","key":"362_CR33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.7326\/M16-0065","volume":"165","author":"JM Freiman","year":"2016","unstructured":"Freiman, J. M. et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: A systematic review and meta-analysis. Ann. Intern. Med. 165(5), 345\u2013355 (2016).","journal-title":"Ann. Intern. Med."},{"key":"362_CR34","unstructured":"Organization WH. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Available from: https:\/\/www.who.int\/choice\/toolkit\/en\/. (last accessed 21 November 2018)."},{"issue":"7","key":"362_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.18553\/jmcp.2011.17.7.531","volume":"17","author":"C McAdam-Marx","year":"2011","unstructured":"McAdam-Marx, C. et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: A managed care perspective. J. Manag. Care Pharm. 17(7), 531\u2013546 (2011).","journal-title":"J. Manag. Care Pharm."},{"key":"362_CR36","unstructured":"The Global Fund. Highest-ever funding allocations announced to fight AIDS, TB and malaria. 2019. Available from: https:\/\/www.theglobalfund.org\/en\/news\/2019-12-18-highest-ever-funding-allocations-announced-to-fight-aids-tb-and-malaria\/. (last accessed 31 January 2020)."},{"issue":"1","key":"362_CR37","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1186\/s12913-019-4635-7","volume":"19","author":"A Radley","year":"2019","unstructured":"Radley, A. et al. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments. BMC Health Serv. Res. 19(1), 765 (2019).","journal-title":"BMC Health Serv. Res."}],"updated-by":[{"DOI":"10.1038\/s41598-022-07001-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00362-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00362-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00362-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:53:06Z","timestamp":1670086386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00362-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-00362-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"13 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-022-07001-0","URL":"https:\/\/doi.org\/10.1038\/s41598-022-07001-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S. Shilton is an employee of The Foundation for Innovative New Diagnostics. Dr. Chhatwal reported receiving grants from the National Science Foundation and Unitaid during the conduct of the study, grants and personal fees from Gilead and Merck & Co outside the submitted work, and served as a partner with Value Analytics Labs outside the submitted work. All other authors have no competing\/conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21382"}}